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Abstract
Galectin-3 (Gal-3), a 31 kDa member of the family of beta-galactoside-binding proteins, has been implicated in the
progression of different human cancers. However, the proposed roles differ widely, ranging from tumor-promoting cellular
functions and negative impact on patient prognosis to tumor-suppressive properties and positive prognostic impact. We
and others have previously identified Gal-3 as overexpressed in pancreatic cancer as compared to chronic pancreatitis and
normal pancreatic tissue. The purpose of this study was thus the comprehensive analysis of putative cellular functions of
Gal-3 by transient as well as stable silencing or overexpression of Gal-3 in a panel of 6 well-established pancreatic cancer cell
lines. Our results confirm that galectin-3 is upregulated at the mRNA level in pancreatic cancer and strongly expressed in the
majority of pancreatic cancer cell lines. In individual cell lines, transient knockdown of Gal-3 expression resulted in moderate
inhibitory effects on proliferation, migration or anchorage-independent growth of the cells, but these effects were not
consistent across the spectrum of analyzed cell lines. Moreover, functional effects of the modulation of Gal-3 expression
were not observed in stable knockdown or overexpression approaches in vitro and did not alter the growth characteristics
of nude mouse xenograft tumors in vivo. Our data thus do not support a direct functional role of Gal-3 in the malignant
transformation of pancreatic epithelial cells, although paracrine or systemic effects of Gal-3 expression are not excluded.
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Introduction
Pancreatic ductal adenocarcinoma, the most common form of
pancreatic cancer, has an overall 5-year survival rate of ,5%. Over
80% of patients present at an advanced disease stage without the
option for potential curative tumor resection [1,2]. Although
chemotherapy combined with a small-molecule inhibitor targeting
EGF receptor signaling has recently been shown to result in a
modest, but significant increase in survival in locally advanced or
metastatic tumors, the prognosis remains dismal, with median
survival not exceeding 6.2 months [3]. Thus, new diagnostic and
therapeuticapproachesthat improveoutcomeare urgently required.
The family of beta-galactoside-binding proteins (Galectins)
consists of 14 members in mammals. A common feature that
distinguishes Galectins from other lectins is their carbohydrate-
recognition domain. Galectin-3 (Gal-3), the 31 kDa member of this
family, has been linked to a variety of tumors, albeit with widely
differingroles[4].Gal-3overexpressionincancerous tissue has been
associated with a poor prognosis in different cancer types including
hepatocellular carcinoma [5,6], clear cell renal carcinoma [7,8] and
bladder cancer [9]. Conversely, reduced Gal-3 expression in tumor
tissue compared with normal tissue was reported in ovarian cancer
[10], uterine adenocarcinoma [11], breast cancer [12,13] and
cervical neoplasia [14]. In colorectal cancer, reports have been
contradictory. Some authors describe a positive association of high
levels of Gal-3 expression with advanced tumor stages and poor
prognosis [15–17], whereas others correlate decreased expression of
Gal-3 with poor prognosis [18–20]. In gastric cancer, Okada et al
reported that reduced Gal-3 expression correlated with lymph node
metastasis and advanced tumor stage [21], whereas two other
groupsidentified increasedexpressionofGal-3 ingastric cancer,but
did not find a correlation with histopathological differentiation or
tumor progression [22,23].
Despite the conflicting results concerning a possible prognostic
role of Gal-3 expression, some reports have described tumor-
promoting functions of Gal-3 in tumor cell lines in vitro.
Knockdown of Gal-3 resulted in reduced cell migration and cell
growth in prostate cancer cells [24], enhanced apoptosis induction
in gastric cancer cells [25], and inhibited in vitro colony formation
as well as nude mouse xenograft induction in breast cancer cells
[26]. We and others have previously shown that Gal-3 is
consistently overexpressed in pancreatic cancer as compared to
both chronic pancreatitis and normal pancreas [27–30]. However,
investigations into a possible functional role of Gal-3 expression in
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this study was thus to experimentally evaluate the effects of
overexpression or knockdown of Gal-3 in a comprehensive set of
pancreatic cancer cell lines (PaTu 8988s, PaTu 8988t, S2-007, S2-
028, IMIM-PC-1 and MIA PaCa-2). Functional analyses included
assays for cell viability, apoptosis, proliferation, migration and
anchorage independent growth as well as tumor growth in a
xenograft mouse model. Apart from isolated effects in single cell
lines, modulation of Gal-3 expression had no consistent effect on
tumor-relevant characteristics of pancreatic cancer cells.
Materials and Methods
Human tissues and cell lines
The human pancreatic adenocarcinoma cell line IMIM-PC-1
[31] was kindly provided by F.X. Real (Insitute Municipale de
Investigacion Medica, Barcelona, Spain). S2-028 and S2-007 [32]
were from T. Iwamura (Miyazaki Medical College, Miyazaki,
Japan). MIA PaCa-2 was obtained from the American Type Culture
Collection (ATCC, RMD, USA). PaTu 8988t and PaTu 8988s were
kindly provided by H.P. Elsa ¨sser (Institut fu ¨r Klinische Zytobiologie
und Zytopathologie, Philipps Universita ¨t, Marburg, Germany). All
cell lines were maintained in Dulbecco’s modified minimal essential
medium (GIBCO, Invitrogen Corp., NY, USA) supplemented with
10% FCS (GIBCO, Invitrogen Corp., NY, USA) and Gentamicin
0.045 mg/ml (GIBCO, Invitrogen Corp., NY, USA).
Ethics Statement
Surgically resected pancreatic adenocarcinoma and chronic
pancreatitis tissues were provided by the surgery departments at
the Universities of Ulm and Homburg/Saar. Normal pancreas
samples were obtained from healthy areas at the borders of
chronic pancreatitis resectates. Written informed consent was
obtained from all patients prior to using tissue samples. The study
was approved by the ethics committee at the University of Ulm,
Germany (Ethikkommission der Universitaet Ulm) as well as the
ethics committee at the University of Homburg/Saar, Germany
(Ethikkommission der Universitaet Homburg).
Transfection of cell lines
Small interfering RNA (siRNA) was transfected into PaTu
8988s, S2-007 and S2-028 cells using siLentFect Lipid Reagent
(Bio-Rad, Munich, Germany) according to the manufacturer’s
protocol. SiRNA transfection into MIA PaCa-2 cells was
performed using Transmessenger reagent (Qiagen, Hilden,
Germany) and IMIM-PC-1 cells were transfected with X-
tremeGENE siRNA Transfection Reagent (Roche, Mannheim,
Germany) according to the manufacturers’ protocols, respectively.
The Gal-3-specific siRNAs were: siGal-3-1, Hs_LGALS3_1
FlexiTube siRNA SI00470036 and siGal-3-2, Hs_LGALS3_2
FlexiTube siRNA SI00470043 (Qiagen). Silencer Negative
Control from Ambion was used as non-silencing control.
The Gal-3 expression vector was constructed by cloning the
PCR-amplified Gal-3 open reading frame into the pcDNA V3.2/
V5 dest vector using the Gateway recombination cloning
technology (Invitrogen Life Technologies, Karlsruhe, Germany).
Following transfection of PaTu 8988t cells using Lipofectamine
2000 Transfection Reagent (Invitrogen), selection of stably
transfected cell clones was performed by adding 800 mg/ml
G418 to the culture medium.
A Gal-3-specific shRNA expression construct in the pGIPZ
vector was purchased from Open Biosystems, Huntsville, AL, USA
(cat. # RHS4430-99137619). Non-silencing shRNAmir (cat. #
RHS4348, Open Biosystems) was used as the negative control.
Stable transfection of the S2-007 cells was performed using
Lipofectamine 2000 (Invitrogen). Stably transfected clones were
selected by adding hygromycin (400 mg/ml) to the culture medium.
RNA Extraction and qRT-PCR
RNA from cell lines was extracted using peqGold Total RNA
Kit (PEQLAB Biotechnologie GmbH, Erlangen, Germany)
according the manufacturer’s protocol. Bulk tumor tissue samples
were homogenized on dry ice/liquid nitrogen using a mortar and
pestle. RNA was extracted using the RNeasy Mini Kit (Qiagen)
according the manufacturer’s protocol. First-strand cDNA was
synthesized from 1 mg total RNA using the Omniscript RT Kit
(Qiagen) according to manufacturer’s protocol. Quantitative real
Figure 1. Overexpression of Gal-3 in pancreatic cancer primary tissues and cell lines. Gal-3 mRNA levels were determined by quantitative
real-time PCR (qRT-PCR) (A, B). Ribosomal protein, large, P0 (RPLP0) was used as the reference gene. PC: pancreatic cancer ; CP: chronic pancreatitis ;
NP: normal pancreas. Protein expression in different pancreatic cancer cell lines was determined by Western blot (C) analyses. b-actin was used as
loading control.
doi:10.1371/journal.pone.0020859.g001
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MasterMix (Applied Biosystems, Wellesley, MA, USA) and specific
primer pairs designed with the PrimerExpresss program (Applied
Biosystems). The following primer pairs were used for qRT–PCR:
ribosomal protein, large, P0 (RPLP0) fwd: 59-TGGGCAAGAA-
CACCATGATG-39; rev. 59-AGTTTCTCCAGAGCTGGGT-
TGT-39; Galectin-3 fwd: 59-AGAGGGAATGATGTTGCC-
TTCC-39; rev: ACAATGACTCTCCTGTTGTTCTCATT-39.
Subcellular fractionation and immunoblotting
Subcellular fractionation was performed as described previously
[33]. Briefly, cells were washed twice with icecold PBS and
collected by centrifugation at 1.600 r.p.m. at 4uC. Lysates were
then resuspended in buffer A (10 mM Hepes pH 7.9; 10 mM
KCl; 0,1 mM EDTA; 0.1 mM EGTA; 1 mM DTT; proteinase
inhibitors) for 15 min and subsequently centrifuged for 20 min at
3.600 r.p.m. Supernatants were transferred to new cups and
centrifuged at 14,000 r.p.m. for additional 4 min. Pellets were
resuspended in 30–100 ml buffer C (20 mM Hepes pH 7.9; 0.4 M
NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM DTT; proteinase
inhibitors) and incubated on ice for 30 min. A final centrifugation
step at 14,000 r.p.m. for 10 min was performed to separate
nuclear proteins from cellular debris. For Western blotting, the
resulting nuclear protein extracts were electrophoresed through a
7.5% SDS–polyacrylamide gel and transferred onto PVDF
Immobilon-P membranes (Millipore, Billerica, MA, USA) as
described previously [34]. Membranes were probed with either
anti-Gal-3 (mouse monoclonal, cat. # A3A12, abcam, Cam-
bridge, UK), anti-ORC2 (polyclonal rabbit, cat. # 559266, BD
Biosciences), anti-PARP (rabbit polyclonal, cat. # 9542, Cell
Figure 2. Silencing and overexpression of Gal-3 in pancreatic cancer cell lines. (A) Transient knockdown of Gal-3 was performed by
transient transfection of multiple cell lines using two different Gal-3 specific siRNA sequences (siGal-3 1 and 2) or a non-silencing control siRNA (NC).
(B) Stable knockdown in S2-007 was performed using shRNA expression constructs. Three Gal-3 specific shRNA transfected clones (shGal-3 1, 2 and 3)
and three nonsilencing control shRNA transfected clones (shC 1, 2 and 3) were chosen for further analysis. (C) Stable overexpression of Gal-3 was
achieved by transfection of PaTu 8988t cells with a Gal-3 expression vector (pGal-3 1, 2 and 3) or a control vector (pC 1 and 2). U denotes
untransfected cells. Total cell lysates were analyzed by qRT-PCR (upper panels) and Western blot (lower panels) for Gal-3 expression levels. Gal-3
mRNA levels were determined relative to RPLP0. siGal-3 1 and 2 were normalized to NC. b-actin was used as loading control for the Western blots.
doi:10.1371/journal.pone.0020859.g002
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monoclonal, cat. # A1978, Sigma-Aldrich, Saint Louis, MI, USA)
antibodies, washed in TBS washing buffer and incubated with
peroxidase-conjugated secondary antibodies. Enhanced chemilu-
minescence reaction system (Roche) was used for visualization.
MTT cell viability assay
Cells were reseeded 24 hours after transfection into 3.9 cm
2
dishes at 60,000 to 100,000 cells/well. After additional 24 h or
48 h of culture, medium was replaced by MTT-containing
medium (thiazolyl blue, Carl Roth, Karlsruhe, Germany) and
dishes were incubated for 2 h at 37uC. The MTT containing
medium was replaced by solubilisation solution (10% Triton X-
100 (Carl Roth), 0.1 molar hydrochloric acid (Fisher Scientific,
Schwerte, Germany) dissolved in isopropanol (Sigma-Aldrich)) and
extinction measured at 570 nm. 48 h values were divided by 24 h
values to correct for possible variations in numbers of seeded cells.
BrdU cell proliferation assay
DNA replication as a direct measure of mitotic activity was
measured using the Cell Proliferation ELISA, BrdU chemilumi-
nescence Kit (Sigma) according to the manufacturer’s protocol.
Briefly, 5,000 to 10,000 cells were reseeded 24 hours after
transfection into a 96 well mClear plates (Greiner Bio-One,
Frickenhausen, Germany). BrdU containing medium was added
for 4 or 6 h. After removal of the BrdU containing medium, cells
were fixed for 1 h and subsequently incubated with the
peroxidase-conjugated anti-BrdU antibody for 1.5 h. The chemi-
luminescence reaction was measured in relative light units per
second (rlu/s).
Trail induced apoptosis
In order to extrinsically induce apoptosis in PaTu 8988s cells,
300,000 cells were seeded in 9.6 cm
2 culture dishes and treated
with Trail protein (R&D Systems, Minneapolis, MN) at a dosage
of 25 ng/ml for 24 h.
Cell migration assay
Modified Boyden chamber assays were performed by reseeding
20,000 to 40,000 cells resuspended in serum free media into
transwell inserts with a pore size of 8 mm (BD Biosciences,
Heidelberg, Germany). Inserts were suspended in 24well plates
filled with medium supplemented with 1% FCS. Cells were
allowed to migrate towards the lower face of the membrane for 2
Figure 3. No effect of Gal-3 knockdown or overexpression on pancreatic cancer cell viability in MTT assay. Transiently Gal-3 silenced
cell lines (A), stably Gal-3 silenced S2-007 cell clones (B) or stably Gal-3 overexpressing PaTu 8988t cell clones (C) were cultured for 24 and 48 h
followed by incubation with MTT reagent. 48 h values were divided by 24 h values (to correct for possible variations in numbers of seeded cells) and
normalized to control siRNA transfected cells (NC). Values of stable Gal-3 knockdown cell clones (shGal-3 1, 2 and 3) and stable Gal-3 overexpressing
cell clones (pGal-3 1, 2 and 3) were normalized to the mean of control vector transfected stable cell clones (shC 1, 2, 3 and pC 1, 2) respectively. Data
includes a minimum of three independent experiments.
doi:10.1371/journal.pone.0020859.g003
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of the inserts using cotton swabs. Migrated cells were stained by
submerging the membranes in 0.2% crystal violet dissolved in
20% methanol for 10 min. Migrated cells were counted using light
microscopy at a magnification of 106.
Soft agar assays
In order to assess the potential for anchorage-independent
growth, soft agar assays were performed as described previously
[35]. In brief, 1610
4 cells per 9.6 cm
2 cell culture dish were
seeded in DMEM/0.33% bacto-agar onto a bottom layer of
DMEM/0.5% bacto-agar. Anchorage-independent growth was
measured after 7 days of incubation by counting the number of
viable colonies.
Nude mouse xenografts
NMRI-nu/nu mice were propagated and maintained in a
pathogen-free environment. Female 6–8-week-old mice were used
in the experiments. To generate xenografts, 10
6 tumor cells in
0.1 ml of serum-free DMEM were injected subcuntaneously into
the flanks of the mice. Three weeks after inoculation, the mice
were sacrificed, tumors were explanted and tumor sizes were
determined. One half of each tumor was stored in 2%
formaldehyde and embedded in paraffin for histological and
immunohistochemical examination. The other half was snap
frozen in liquid nitrogen for RNA and protein isolation.
Results
Overexpression of Gal-3 in pancreatic cancer
In previous high-content microarray analyses, we have
identified Gal-3 as one of the genes overexpressed in microdis-
sected pancreatic cancer tissues [28]. In order to validate these
results, we performed quantitative RealTime PCR (qRT-PCR) on
a set of tissue samples including 10 pancreatic cancer, 5 chronic
pancreatitis and 5 normal pancreatic tissue specimens. Gal-3
mRNA levels were slightly elevated in the chronic pancreatits
samples, and were strongly upregulated in the majority of cancer
samples (Fig. 1A), confirming the microarray data. Subsequent
analysis of pancreatic cancer cell lines demonstrated strong
Figure 4. Inconsistent effect of Gal-3 on cell proliferation as measured by BrdU uptake. Transiently Gal-3 silenced cell lines (A), stably Gal-
3 silenced S2-007 cell clones (B) or stably Gal-3 overexpressing PaTu 8988t cell clones (C) were cultured with BrdU agent for 2 or 4 h. BrdU
incorporation by proliferating cells was measured by ELISA. Values of cells transiently transfected with different Gal-3 specific siRNAs (siGal-3 1 and 2)
were normalized to control siRNA transfected cells (NC). Values of stable Gal-3 knockdown cell clones (shGal-3 1, 2 and 3) and stable Gal-3
overexpressing cell clones (pGal-3 1, 2 and 3) were normalized to the mean of control vector transfected stable cell clones (shC 1, 2, 3 and pC 1, 2)
respectively. Data includes a minimum of three independent experiments. * Indicates p,0.05 as compared with control siRNA transfected cells
(double-sided unpaired t-test).
doi:10.1371/journal.pone.0020859.g004
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out of 6 tested cell lines (Fig. 1B).
Expression level of Gal-3 has no influence on tumor cell
growth in vitro
To assess the functional role of the aberrantly expressed Gal-3
in pancreatic cancer cells, Gal-3 was transiently or stably
overexpressed or silenced in different pancreatic cancer cell lines
and the effects analyzed in various in vitro functional assays. For
transient silencing, two independent siRNA sequences as well as a
non-silencing control siRNA were used. For each of the five cell
lines analyzed (PaTu 8988s, S2-007, S2-028, IMIM-PC-1 and
MIA PaCa-2), transfection reagents and –conditions were
optimized to achieve knockdown efficiencies .80% (Fig. 2A).
Stable knockdown clones were generated using S2-007 cells
transfected with shRNA sequences cloned in the pGIPZ vector.
Three stably transfected clones as well as three control vector
transfected clones were chosen for further analysis (Fig. 2B).
Since PaTu 8988t cells showed very low endogenous Gal-3 levels,
this cell line was chosen for the construction of stable Gal-3
overexpressing clones. Three independent clones were established.
Two of these showed moderate overexpression of recombinant Gal-
3 on the mRNA level, which was much more pronounced on the
protein level (Fig. 2C, lanes 4, 6). The remaining clone did not show
appreciable expression of recombinant Gal-3 (Fig. 2C, lane 5), but
was included in the further experiments as additional control clone.
Interestingly, control clones transfected with empty vector also
showed somewhat elevated Gal-3 levels (Fig. 2C, lanes 2, 3).
In a first functional assay, the influence of Gal-3 expression on
cell viability was analyzed by MTT assays. Neither transient
knockdown in any of the 5 tested cell lines, nor stable knockdown
in S2-007 cells or stable overexpression in PaTu 8988t cells had
any significant effect on cell viability under normal culture
conditions as compared to the suitable controls (Fig. 3 A–C).
Analysis of cell proliferation using BrdU assays revealed a
moderate, but significant inhibition of proliferative activity in S2-
028 cells after knockdown of Gal-3 (Fig. 4A, panel 3). However,
the trend to reduced proliferation did not reach significance in
PaTu 8988s and S2-007 cells, was absent in IMIM-PC-1 and even
reversed in MIA PaCa-2 cells (Fig. 4A). Neither stable knockdown
in S2-007 cells, nor stable overexpression of Gal-3 in PaTu 8988t
cells had any significant effect on proliferation of the resulting cell
clones.
Likewise, transient Gal-3 knockdown had no effect on apoptotic
activity (as measured by PARP cleavage) of PaTu 8988s cells in the
absence (Fig. 5, lanes 1–4) or presence (Fig. 5, lanes 5–8) of the
extrinsic apoptosis inducer Trail. PARP cleavage was induced by
the transfection procedure and was more pronounced in the
presence of Trail (Fig. 5, lanes 2 and 6), but was not further
enhanced by knockdown of Gal-3 (Fig. 5, lanes 3–4 and 7–8).
Replication of this set of experiments under serum-free
conditions produced similar results, failing to demonstrate any
consistent influence of the modulation of Gal-3 expression on cell
growth or apoptosis in the tested cell lines (data not shown).
Inconsistent effect of Gal-3 on cell migration
We ext analyzed the influence of Gal-3 expression on cell
migration in a Boyden chamber assay. Cells were able to
transmigrate through a filter along a fetal calf serum gradient.
Numbers of transiently Gal-3 silenced migrated cells were
normalized to non-silencing control siRNA transfected cells.
Transient knockdown of Gal-3 resulted in a trend towards
decreased cell migration in three out of five analysed cell lines,
although this effect did not reach significance in most instances
(Fig. 6A). Moreover, this effect was not reproduced in the S2-007
cell clones with stable Gal-3 knockdown (Fig. 6, B). In reverse
analogy to the results of the transient knockdown experiments,
stable overexpression of Gal-3 in PaTu 8988t cells induced a trend
towards increased cell migration (Fig. 6, C), although this trend
again did not reach significance and was also apparent in clone
pGal-3 2, which showed low or absent expression of recombinant
Gal-3 (see Fig. 2C). Taken together, modulation of Gal-3
expression had a mild and rather inconsistent effect in the Boyden
chamber assays, thus arguing against an important role of cellular
Gal-3 in directed migration of pancreatic cancer cells.
Inhibition of Gal-3 expression impairs anchorage
independent growth in a subset of pancreatic cancer
cell lines but has no effect on growth of xenograft
tumors in vivo
The potential for anchorage-independent growth of the cancer
cells was assessed by evaluating the numbers of colonies formed in
soft agar assays. Transient knockdown of Gal-3 resulted in a clear
reduction in colony formation capacity for the cell lines PaTu
8988s, S2-007 and IMIM-PC-1, with the strongest effect and
highest statistical significance observed for S2-007 cells (Fig. 7A).
Conversely, S2-028 and MIA PaCa-2 cells were not affected by
the Gal-3 knockdown. Since previous reports had indicated that
tumor-promoting functions of Gal-3 in other cell systems may
depend on the subcellular localization of the protein [26,36,37],
we analyzed whether the differential effect of Gal-3 knockdown
colony forming capacity correlated with different subcellular
localization of Gal-3 in the tested cell lines. Gal-3 protein was
evenly distributed between nucleus and cytosol in MIA PaCa-2
and S2-007 cells and was slightly overrepresented in the cytosolic
fractions in PaTu 8988s, S2-028 and IMIM-PC-1 cells (Fig. 7B),
thus showing no correlation with sensitivity towards Gal-3
knockdown.
We then tested if the effect on anchorage-independent growth
in S2-007 cells also translated into differences in tumor growth
in vivo.
Figure 5. No effect of transient Gal-3 knockdown on caspase-
dependent apoptosis in PaTu 8988s cells. Cells transiently
transfected with Gal-3 specific siRNAs (siGal-3 1 and 2), nonsilencing
control siRNA (NC) or untransfected cells (U) were analyzed by Western
blot for poly ADP-ribose polymerase (PARP) cleavage. Increased
cleavage, indicated by the enhanced signal of the lower band, was
seen in all transfected cells. PARP cleavage was enhanced by treatment
with the extrinsic apoptosis inducer Trail, but was not influenced by
Gal-3 knockdown. b-actin was used as loading control. Results shown
are representative of three individual experiments.
doi:10.1371/journal.pone.0020859.g005
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subcutaneous injection of S2-007 cells with stable Gal-3
knockdown or control vector-transfected cells, respectively. No
significant difference in tumor volumes between Gal-3 knockdown
and control tumors was observed (Fig. 7C). Histological exami-
nation of the tumors also did not reveal any systematic differences
in differentiation, local invasiveness or microvessel density between
the different groups (data not shown).
In order to confirm persistent reduction of Gal-3 levels in the
knockdown tumors, mRNA was prepared from bulk tumor tissue
and analyzed by qRT PCR. As expected, Gal-3 mRNA levels
were significantly lower in the tumors derived from the S2-007
knockdown clones than in those derived from the control vector-
transfected clones (Fig. 7D).
Discussion
Deregulation of Gal-3 expression has been described in several
human cancers, although the prognostic significance of the
observed changes remains a matter of controversy [37,38].
Pancreatic ductal adenocarcinoma is among those human tumors
in which a significant overexpression of Gal-3 both on mRNA as
well as on the protein level is well established [27,30]. Our own
results from microarray analyses of microdissected pancreatic
tumor tissues indicated that Gal-3 is expressed by the tumor cells
themselves rather than by the stromal cells which typically make
up the bulk of the tumor [28]. In the current study, we confirm
overexpression of Gal-3 mRNA in the tumor tissues by qRT-PCR
and demonstrate that strong Gal-3 expression is retained in the
majority of pancreatic cancer cell lines in vitro.
As is the case with data on the prognostic role in cancer, reports
on putative cellular functions of Gal-3 in cancer cells are in part
inconclusive or even contradictory. While Honjo et al. report loss
of (serum-independent) proliferative capacity and abrogation of
anchorage-independent growth in breast cancer cells following
silencing of Gal-3 expression [26], Matarrese et al. did not observe
any difference in cell growth or proliferation upon modulation of
Gal-3 expression, but describe enhanced resistance to apoptosis
following overexpression of Gal-3 [36]. Likewise, the same group
that observed the growth inhibitory effects of Gal-3 silencing in
Figure 6. Inconsistent effect of Gal-3 knockdown and overexpression on cell migration as measured by Boyden-chamber assay.
Transiently Gal-3 silenced cell lines (A), stably Gal-3 silenced S2-007 cell clones (B) or stably Gal-3 overexpressing PaTu 8988t cell clones (C) were
cultured in Boyden-chamber inserts for 2 or 4 h. Cells migrating through the pores of the inserts along a fetal calf serum gradient were fixed, stained
methylene blue and counted using light microscopy. Numbers of migrated cells transiently transfected with different Gal-3 specific siRNA (siGal-3 1
and 2) were normalized to control siRNA transfected cells (NC). Migrated stable Gal-3 knockdown cells (shGal-3 1, 2 and 3) and stable Gal-3
overexpressing cells (pGal-3 1, 2 and 3) were normalized to the mean of control vector transfected stable cell clones (shC 1, 2, 3 and pC 1, 2)
respectively. Data includes a minimum of three independent experiments. * Indicates p,0.05 as compared with control siRNA transfected cells
(double-sided unpaired t-test).
doi:10.1371/journal.pone.0020859.g006
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knockdown in prostate cancer cells, including reduced cell
migration, invasion, cell proliferation, anchorage-independent
colony formation, and tumor growth in nude mouse xenografts
[24]. In contrast, Califice et al. did not observe any effect of Gal-3
expression on proliferation of prostate cancer cells in any
constellation, and reported that Matrigel invasion, anchorage-
independent growth and nude mouse xenograft formation was
promoted only by cytoplasmic Gal-3 expression, while nuclear
localization of Gal-3 had the opposite effect [37].
A common theme in many of these studies is the fact that often
very few or only a single cell line was analyzed, and that some of
the effects were only observed under very specific experimental
conditions. We therefore decided to conduct a comprehensive
study on the putative role of Gal-3 in pancreatic cancer cells by
analyzing in parallel the effect of transient silencing of Gal-3 in a
panel of five well-established cell lines with high endogenous Gal-3
expression, as well as study the long-term effects of modulation of
Gal-3 expression by stable knockdown in S2-007 cells (high
endogenous Gal-3 expression) or stable overexpression in PaTu
8988t cells (negligible endogenous Gal-3 expression), respectively.
Our results demonstrate that transient knockdown of Gal-3
expression resulted in moderate inhibitory effects on proliferation,
migration or anchorage-independent growth in individual pan-
creatic cancer cell lines. These isolated effects were reminiscent of
some of the results described in other in vitro cancer cell systems.
However, although the five cell lines expressed endogeneous Gal-3
at very comparable levels, both on the mRNA as well as on the
protein level, functional effects remained limited to individual cell
lines and failed to show a consistent pattern across the spectrum of
analyzed cell lines. Subcellular localization of the protein did not
vary systematically and did not provide an explanation for the
differences in susceptibility to Gal-3 knockdown, contrary to the
suggestion by Califice et al. [37].
Moreover, functional effects of the modulation of Gal-3
expression were not observed in stable knockdown or overexpres-
sion approaches in vitro. Most importantly, the attenuation of
anchorage-independent growth of S2-007 cells after transient
Gal-3 knockdown did not translate into significant differences in
growth characteristics of stable knockdown and control clones in
nude mouse xenograft tumors in vivo.
While this manuscript was in preparation, a study by Kobayashi
et al. was published that examined the effects of transient Gal-3
silencing in Panc-1, AsPC-1 and BxPc-3 pancreatic cancer cell
lines [39]. Similar to our results, the authors observed no influence
on proliferation of the cells, but contrary to our results describe an
inhibitory effect of Gal-3 knockdown on cell migration and
invasion. While the observed effects were consistent across the
three cell lines, only one siRNA sequence was used in the study,
and no in vivo experiments were performed. It is interesting to note
that in our experiments, we observed significant inhibition of cell
migration in S2-007 and MIA PaCa-2 cells with one of the two
siRNAs used (siGal-3 1); however, this effect was not observed for
siGal-3 2, and was altogether absent in the other cell lines (Fig. 6).
From the data presented by Kobayashi et al., it can not be ruled
out that the observed effects were either specific to the three cell
lines used and/or were attributable to off-target effects of the single
siRNA used in the study.
Our results do not rule out paracrine and/or systemic effects of
the expression of (secreted) Gal-3 by pancreatic cancer cells. Jiang
et al. have recently suggested that Gal-3 plays a role in the
interaction between SW1990 pancreatic cancer cells and special-
ized stromal cells of the pancreas termed pancreatic stellate cells
(PSC) [40]. In another very recent study, Senapati et al. described
that binding of exogenous Gal-3 to MUC4 on the cell surface of
CD18/HPAF pancreatic cancer cells enhanced the attachment of
the cancer cells to HUVEC endothelial cells in in vitro assays,
speculating that MUC4/Gal-3 interaction may facilitate extrav-
asation and metastasis of tumor cells in vivo [41]. However, the
clinical significance of these observations remains unclear,
especially in view of the fact that no Gal-3 secretion by CD18/
HPAF cells was detected. Moreover, in a large study with 104
pancreatic cancer cases, Shimamura et al. reported a statistically
highly significant correlation of high expression of Gal-3 in the
primary tumors with reduced metastatic potential and increased
post-operative survival [42].
In summary, experimental data on the putative pathophysiological
role(s) of Gal-3 in cancer remain controversial, and a clear picture of
the function of Gal-3 in the onset and progression of cancer in general
as well as pancreatic cancer in particular is not yet emerging.
Author Contributions
Conceived and designed the experiments: MB TMG. Performed the
experiments: AH AG. Analyzed the data: AH MB AG. Contributed
reagents/materials/analysis tools: YC. Wrote the paper: AH. First authors:
AH AG. Senior authors: TMG MB.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362: 1605–
1617.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus
gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada
Clinical Trials Group. J Clin Oncol 25: 1960–1966.
4. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression.
Nat Rev Cancer 5: 29–41.
5. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, et al. (1999) Galectin-3
expression is induced in cirrhotic liver and hepatocellularcarcinoma. Int JCancer
81: 519–526.
6. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T (2008)
Expression of galectin-3 involved in prognosis of patients with hepatocellular
carcinoma. Hepatol Res 38: 1098–1111.
Figure 7. Gal-3 knockdown decreases anchorage independent cell growth, but has no effect on tumor growth in a xenograft mouse
model. (A) Gal-3 was transiently silenced in pancreatic cancer cell lines using two independent siRNA sequences (siGal-3 1 and 2). Knockdown and
control cells were seeded in soft agar and colony formation assessed after 7 days. Results were normalized to control siRNA transfected cells (NC). Data
includes a minimum of three independent experiments. * Indicates p,0.05 as compared with control siRNA transfected cells (double-sided unpaired t-
test). (B) Western blot analysis of nuclear (n) andcytoplasmatic (c) protein fractions derived from pancreatic cancer cell lines.Gal-3 is shown in the upper
lane. b-actin staining was used as loading control. Staining for the nuclear factor ORC2 was used to assess the purity of the subcellular fractions. (C)
Xenograft tumors were induced in nude mice by subcutaneous injection of two stable Gal-3 knockdown S2-007 cell clones (shGal-3 2 and 3) and two
nonsilencing control shRNA transfected S2-007 clones (shC 2 and 3). Six mice per experimental group were analyzed. Box-and-whisker plots illustrate
tumor volumes on day 22 post injection. Whiskersdenote 1.56interquartile range (IQR). Values outside this range areshown as filled triangles. (D) Gal-3
mRNA levels in bulk tissue of xenograft tumors where determined by qRT-PCR. RPLP0 was used as the reference gene.
doi:10.1371/journal.pone.0020859.g007
Galectin-3 in Pancreatic Cancer
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e208597. Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, et al. (2010)
Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest
57: 152–157.
8. Dancer JY, Truong LD, Zhai Q, Shen SS (2010) Expression of Galectin-3 in
renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med
134: 90–94.
9. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, et al.
(2010) Galectin-3 expression is associated with bladder cancer progression and
clinical outcome. Tumour Biol 31: 277–285.
10. van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, et al. (1994)
Differential expression of the 67-kD laminin receptor and 31-kD human
laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A:
1096–1099.
11. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, et al. (1996)
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced
human uterine adenocarcinoma. Hum Pathol 27: 1185–1191.
12. Castronovo V, van den Brule FA, Jackers P, Clausse N, Liu FT, et al. (1996)
Decreased expression of galectin-3 is associated with progression of human
breast cancer. J Pathol 179: 43–48.
13. Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation
with cancer histologic grade. Int J Oncol 12: 1287–1290.
14. Lee JW, Song SY, Choi JJ, Choi CH, Kim TJ, et al. (2006) Decreased galectin-3
expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol
132: 241–247.
15. Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an
endogenous galactose-binding lectin correlates with neoplastic progression in the
colon. Cancer 75: 2818–2826.
16. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, et al. (1999)
Involvement of galectin-3 expression in colorectal cancer progression and
metastasis. Int J Oncol 15: 143–148.
17. Irimura T, Matsushita Y, Sutton RC, Carralero D, Ohannesian DW, et al.
(1991) Increased content of an endogenous lactose-binding lectin in human
colorectal carcinoma progressed to metastatic stages. Cancer Res 51: 387–393.
18. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, et al.
(1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer
progression. Gastroenterology 113: 1906–1915.
19. Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, et al.
(1992) Inverse modulation of steady-state messenger RNA levels of two non-
integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst
84: 1161–1169.
20. Lotz MM, Andrews CW, Jr., Korzelius CA, Lee EC, Steele GD, Jr., et al. (1993)
Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its
nuclear localization are associated with the neoplastic progression of colon
carcinoma. Proc Natl Acad Sci U S A 90: 3466–3470.
21. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H (2006) Reduced
galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer.
Anticancer Res 26: 1369–1376.
22. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, et al. (2000)
Increased galectin-3 expression in gastric cancer: correlations with histopatho-
logical subtypes, galactosylated antigens and tumor cell proliferation. Tumour
Biol 21: 258–266.
23. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, et al. (1994) Expression of a 31-
kDa lactoside-binding lectin in normal human gastric mucosa and in primary
and metastatic gastric carcinomas. Int J Cancer 56: 474–480.
24. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, et al. (2009) Regulation
of prostate cancer progression by galectin-3. Am J Pathol 174: 1515–1523.
25. Cheong TC, Shin JY, Chun KH (2010) Silencing of galectin-3 changes the gene
expression and augments the sensitivity of gastric cancer cells to chemothera-
peutic agents. Cancer Sci 101: 94–102.
26. Honjo Y, Nangia-Makker P, Inohara H, Raz A (2001) Down-regulation of
galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin
Cancer Res 7: 661–668.
27. Berberat PO, Friess H, Wang L, Zhu Z, Bley T, et al. (2001) Comparative
analysis of galectins in primary tumors and tumor metastasis in human
pancreatic cancer. J Histochem Cytochem 49: 539–549.
28. Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, et al. (2005)
Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic
lesions. Oncogene 24: 6626–6636.
29. Lu Z, Hu L, Evers S, Chen J, Shen Y (2004) Differential expression profiling of
human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 4:
3975–3988.
30. Schaffert C, Pour PM, Chaney WG (1998) Localization of galectin-3 in normal
and diseased pancreatic tissue. Int J Pancreatol 23: 1–9.
31. Vila MR, Lloreta J, Schussler MH, Berrozpe G, Welt S, et al. (1995) New
pancreas cancers cell lines that represent distinct stages of ductal differentiation.
Lab Invest 72: 395–404.
32. Taniguchi S, Iwamura T, Katsuki T (1992) Correlation between spontaneous
metastatic potential and type I collagenolytic activity in a human pancreatic
cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis 10: 259–266.
33. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of
octamer binding proteins with ‘mini-extracts’, prepared from a small number of
cells. Nucleic Acids Res 17: 6419.
34. Ellenrieder V, Buck A, Harth A, Jungert K, Buchholz M, et al. (2004) KLF11
mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-
MAPK in pancreatic cancer cells. Gastroenterology 127: 607–620.
35. Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, et al. (2003)
SERPINE2 (protease nexin I) promotes extracellular matrix production and
local invasion of pancreatic tumors in vivo. Cancer Res 63: 4945–4951.
36. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, et al. (2000) Galectin-3
overexpression protects from apoptosis by improving cell adhesion properties.
Int J Cancer 85: 545–554.
37. Califice S, Castronovo V, Bracke M, van den Brule F (2004) Dual activities of
galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs
tumor promotion of cytoplasmic galectin-3. Oncogene 23: 7527–7536.
38. Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim
Biophys Acta 1760: 616–635.
39. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, et al. (2011) Transient
gene silencing of galectin-3 suppresses pancreatic cancer cell migration and
invasion through degradation of beta-catenin. Int J Cancer (Epub ahead of print;
doi: 10.1002/ijc.25946).
40. Jiang HB, Xu M, Wang XP (2008) Pancreatic stellate cells promote proliferation
and invasiveness of human pancreatic cancer cells via galectin-3.
World J Gastroenterol 14: 2023–2028.
41. Senapati S, Chaturvedi P, Chaney WG, Chakraborty S, Gnanapragassam VS,
et al. (2011) Novel INTeraction of MUC4 and galectin: potential pathobiological
implications for metastasis in lethal pancreatic cancer. Clin Cancer Res 17:
267–274.
42. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, et al. (2002)
Clinicopathological significance of galectin-3 expression in ductal adenocarci-
noma of the pancreas. Clin Cancer Res 8: 2570–2575.
Galectin-3 in Pancreatic Cancer
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20859